Neuroone Medical Technologies CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
NeuroOne Medical Technologies Corporation filed an amendment to its annual report to provide detailed information on executive compensation, corporate governance, and related party transactions for the fiscal year ended September 30, 2025.
NASDAQ
NeuroOne Medical Technologies Corporation announced significant product and collaboration revenue growth, leading to a substantial reduction in net loss for the fiscal year ended September 30, 2025, despite ongoing concerns about its ability to continue as a going concern.
NASDAQ
NeuroOne Medical Technologies Corporation's 10-K filing details its financial performance for fiscal year 2024, ongoing product development, and strategic initiatives in the neuromodulation space.